Alendronic acid +/- colecalciferol in postmenopausal women with osteoporosis: effects on levels of parathyroid hormone and bone turnover markers

Trial Profile

Alendronic acid +/- colecalciferol in postmenopausal women with osteoporosis: effects on levels of parathyroid hormone and bone turnover markers

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2013

At a glance

  • Drugs Colecalciferol (Primary) ; Alendronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 10 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top